0001193125-24-158461.txt : 20240611 0001193125-24-158461.hdr.sgml : 20240611 20240610173202 ACCESSION NUMBER: 0001193125-24-158461 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240610 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240611 DATE AS OF CHANGE: 20240610 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Atara Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001604464 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 460920988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36548 FILM NUMBER: 241033901 BUSINESS ADDRESS: STREET 1: 2380 CONEJO SPECTRUM ST STREET 2: SUITE 200 CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: 805-623-4244 MAIL ADDRESS: STREET 1: 2380 CONEJO SPECTRUM ST STREET 2: SUITE 200 CITY: THOUSAND OAKS STATE: CA ZIP: 91320 8-K 1 d741804d8k.htm 8-K 8-K
false 0001604464 0001604464 2024-06-10 2024-06-10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 10, 2024

 

 

Atara Biotherapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-36548   46-0920988
(State or Other Jurisdiction
of Incorporation)		   (Commission
File No.)		   (IRS Employer
Identification No.)

 

2380 Conejo Spectrum St, Suite 200

Thousand Oaks, CA

   91320
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (805) 632-4211

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities pursuant to Section 12 (b) of the Act:

 

Title of Each Class

  

Trading
Symbol(s)

  

Name of Each Exchange
on Which Registered

Common Stock, par value $0.0001 per share   ATRA   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 10, 2024, Atara Biotherapeutics, Inc. (the “Company”) held its 2024 annual meeting of stockholders (the “Annual Meeting”). The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for or against each matter and the number of abstentions and broker non-votes with respect to each matter. A more complete description of each matter is described in more detail in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 26, 2024, as supplemented on May 10, 2024 (the “Proxy Statement”).

 

1.

Election of Directors

 

Nominee

  

For

  

Withheld

  

Broker Non-Votes

William K. Heiden

   64,365,411   6,765,961   24,841,883

Ameet Mallik

   58,254,661   12,876,711   24,841,883

Each of the two nominees for director was elected to serve until the 2027 annual meeting of stockholders and until their respective successors are elected.

 

2.

Advisory vote to approve on the compensation of the Company’s named executive officers

 

For

  

Against

  

Abstain

  

Broker Non-Votes

63,970,487

   6,810,564   350,321   24,841,883

The stockholders approved, on an advisory basis, the compensation awarded to the Company’s named executive officers, as disclosed in the Proxy Statement.

 

3.

Ratification of appointment of independent registered public accounting firm

 

For

  

Against

  

Abstentions

89,685,078

   6,077,689   210,488

The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.

 

4.

Approval of the Company’s 2024 Equity Incentive Plan

 

For

  

Against

  

Abstain

  

Broker Non-Votes

53,961,768

   16,999,707   169,897   24,841,883

The stockholders approved the Company’s 2024 Equity Incentive Plan.

 

5.

Approval of automatic annual increase to the Company’s 2024 Equity Incentive Plan

 

For

  

Against

  

Abstain

  

Broker Non-Votes

26,632,385

   44,285,524   213,463   24,841,883

The stockholders did not approve the automatic annual increase to the Company’s 2024 Equity Incentive Plan.

 

6.

Approval of increase in number of common stock available for issuance under Company’s 2014 Employee Stock Purchase Plan

 

For

  

Against

  

Abstain

  

Broker Non-Votes

64,172,319

   6,917,348   41,705   24,841,883

The stockholders approved the increase in the number of shares of common stock available for issuance under the Company’s 2014 Employee Stock Purchase Plan.

7.

Approval of amendment to Company’s Certificate of Incorporation to effect a reverse stock split

 

For

  

Against

  

Abstentions

85,657,554

   9,877,294   438,407

The stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to effect a reverse stock split of the Company’s common stock at a ratio ranging from any whole number between 1-for-4 and 1-for-30, as determined by the Company’s Board of Directors in its discretion, subject to the Company’s Board of Directors’ authority to abandon such amendments.

 

8.

Approval of adjournment of the annual meeting for further solicitation

 

For

  

Against

  

Abstentions

80,507,780

   14,437,998   1,027,477

The stockholders approved the adjournment of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes in favor of the amendment to the Company’s amended and restated certificate of incorporation to effect a reverse stock split of the Company’s common stock.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Atara Biotherapeutics, Inc.
By:  

/s/ Amar Murugan

  Amar Murugan
  Executive Vice President and Chief Legal Officer

Date: June 10, 2024

EX-101.SCH 2 atra-20240610.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 atra-20240610_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 atra-20240610_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
Jun. 10, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001604464
Document Type 8-K
Document Period End Date Jun. 10, 2024
Entity Registrant Name Atara Biotherapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-36548
Entity Tax Identification Number 46-0920988
Entity Address, Address Line One 2380 Conejo Spectrum St
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Thousand Oaks
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91320
City Area Code (805)
Local Phone Number 632-4211
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol ATRA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports atra-20240610.xsd atra-20240610_lab.xml atra-20240610_pre.xml d741804d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d741804d8k.htm": { "nsprefix": "atra", "nsuri": "http://www.atarabio.com/20240610", "dts": { "schema": { "local": [ "atra-20240610.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "atra-20240610_lab.xml" ] }, "presentationLink": { "local": [ "atra-20240610_pre.xml" ] }, "inline": { "local": [ "d741804d8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-06-10_to_2024-06-10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d741804d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-06-10_to_2024-06-10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d741804d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.atarabio.com//20240610/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001193125-24-158461-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-158461-xbrl.zip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end XML 16 d741804d8k_htm.xml IDEA: XBRL DOCUMENT 0001604464 2024-06-10 2024-06-10 false 0001604464 8-K 2024-06-10 Atara Biotherapeutics, Inc. DE 001-36548 46-0920988 2380 Conejo Spectrum St Suite 200 Thousand Oaks CA 91320 (805) 632-4211 false false false false Common Stock, par value $0.0001 per share ATRA NASDAQ false